Clinical genitourinary cancer · 2025
Long-Term Mortality Trends From Prostate Cancer and Associated Second Malignancies in the U.S., 1999 to 2023: Implications for Survivorship Care.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rath Shree, Lal Amar, Hasan Ahmed, Ali Muhammad, Sultan Laiba, Khan Mishaim, Alam Umama
Аннотация
INTRODUCTION: Prostate cancer remains the most commonly diagnosed malignancy among men in the United States. However, the risk and burden of secondary malignancies (SMs) among this group are not well characterized. This study examines national trends in mortality attributable to SMs among prostate cancer survivors, with an emphasis on demographic and geographic disparities.
METHODS: Utilizing data from the CDC WONDER, we conducted a population-based analysis of mortality rates linked to SPMs in individuals aged 65 and older with a prior prostate cancer diagnosis, spanning 1999 to 2023. Age-adjusted mortality rates (AAMRs) were calculated per 100,000 population and stratified by age, race/ethnicity, region, and urbanization. Joinpoint regression was used to assess changes in trends and annual percent change (APC).
RESULTS: From 1999 to 2023, a total of 115,041 deaths were attributed to SMs in prostate cancer, with an overall Age-adjusted mortality rate (AAMR) of 26.21 (95% CI, 25.43-26.99). Trends showed a significant decline from 1999 to 2006, followed by a significant rise in the periods of 2013 to 2017 (APC = 8.17%) and 2017 to 2023 (APC = 4.71; 95% CI, 3.03-5.5.75). Racial disparities were evident, with non-Hispanic White individuals exhibiting an overall incline in contrast to non-Hispanic Black individuals, who experienced a decrease. Notably, men aged 85 years and older had a statistically significant long-term rise in mortality (AAPC = 0.92), in contrast with younger groups, which demonstrated early declines and nonsignificant long-term trends.
CONCLUSIONS: Mortality from SMs among U.S. prostate cancer survivors has increased in complexity over the past 24 years, with pronounced disparities by race, region, urbanization, and age group. These findings highlight the need for enhanced survivorship care, targeted screening, and public health interventions to address growing risks and ensure equitable outcomes for all affected populations.
METHODS: Utilizing data from the CDC WONDER, we conducted a population-based analysis of mortality rates linked to SPMs in individuals aged 65 and older with a prior prostate cancer diagnosis, spanning 1999 to 2023. Age-adjusted mortality rates (AAMRs) were calculated per 100,000 population and stratified by age, race/ethnicity, region, and urbanization. Joinpoint regression was used to assess changes in trends and annual percent change (APC).
RESULTS: From 1999 to 2023, a total of 115,041 deaths were attributed to SMs in prostate cancer, with an overall Age-adjusted mortality rate (AAMR) of 26.21 (95% CI, 25.43-26.99). Trends showed a significant decline from 1999 to 2006, followed by a significant rise in the periods of 2013 to 2017 (APC = 8.17%) and 2017 to 2023 (APC = 4.71; 95% CI, 3.03-5.5.75). Racial disparities were evident, with non-Hispanic White individuals exhibiting an overall incline in contrast to non-Hispanic Black individuals, who experienced a decrease. Notably, men aged 85 years and older had a statistically significant long-term rise in mortality (AAPC = 0.92), in contrast with younger groups, which demonstrated early declines and nonsignificant long-term trends.
CONCLUSIONS: Mortality from SMs among U.S. prostate cancer survivors has increased in complexity over the past 24 years, with pronounced disparities by race, region, urbanization, and age group. These findings highlight the need for enhanced survivorship care, targeted screening, and public health interventions to address growing risks and ensure equitable outcomes for all affected populations.